Long-term follow-up of BRL-101 for thalassemia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study follows people who have already received BRL-101 treatment for transfusion-dependent beta-thalassemia to check their health over time. It helps doctors understand how well the treatment works in the long run.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already received the study treatment BRL-101 for beta-thalassemia that requires regular blood transfusions.
- You (or your parent/guardian) must agree to join the study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients who have already been treated with BRL-101 for transfusion-dependent beta-thalassemia. Its goal is to track long-term outcomes and safety.
This study follows up on people who have already received the CS-101 infusion in a previous trial. It aims to check how participants are doing over time. There are no restrictions to join if you already received CS-101.
This study follows up with people who already received the CS-101 injection in a previous trial to check its safety and how well it works over time.
This trial tests a new treatment called CS-101 for people with beta-thalassemia who need regular blood transfusions. It aims to see if CS-101 can help reduce transfusion needs.
This trial tests a new treatment called BRL-101 for people with severe sickle cell disease. The treatment uses your own stem cells, which are modified in the lab and then given back to you. It aims to reduce pain crises and improve your quality of life.
This study tests an experimental drug called YOLT-204 to see if it is safe and can help people with transfusion-dependent beta-thalassemia need fewer blood transfusions. It is for adults aged 18 to 35 who have a specific type of thalassemia and are otherwise healthy enough for the trial.
Hear when a new Thalassemia, Beta trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.